130290-79-8

Basic information

• Product Name: 4-(Aminomethyl)tetrahydro-2H-pyran
• Synonyms: C-(TETRAHYDRO-PYRAN-4-YL)-METHYLAMINE;ASINEX-REAG BAS 07731534;1-TETRAHYDRO-2H-PYRAN-4-YLMETHANAMINE;4-AMINOMETHYLTETRAHYDROPYRAN;(TETRAHYDROPYRAN-4-YL)METHYLAMINE;(TETRAHYDRO-2H-PYRAN-4-YL) METHANAMINE;(TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINE;4-(Aminomethyl)tetrahydropyrane
• CAS NO: 130290-79-8
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 115.17
• EINECS: 1592732-453-0
• Product Categories: Amines;blocks;Heterocycles;Aminomethyl's;Pyrans, Piperidines & Piperazines
• Mol File: 130290-79-8.mol

Chemical Properties

• Boiling Point: 75 °C
• Flash Point: 64.9 °C
• Appearance: clear colorless liquid
• Density: 1.02
• Vapor Pressure: 0.912mmHg at 25°C
• Refractive Index: 1.4630-1.4670
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.01±0.29(Predicted)
• CAS DataBase Reference: 4-(Aminomethyl)tetrahydro-2H-pyran(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Aminomethyl)tetrahydro-2H-pyran(130290-79-8)
• EPA Substance Registry System: 4-(Aminomethyl)tetrahydro-2H-pyran(130290-79-8)

Safety Data

• Hazard Codes: Xi,C,Xn
• Statements: 34-41-37/38-22
• Safety Statements: 26-36/37/39-45-39
• RIDADR: 2735
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 130290-79-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(Aminomethyl)tetrahydro-2H-pyran is used as a reagent for core modification in the discovery of CC214-2, which is an orally available, selective inhibitor of mTOR kinase. 4-(Aminomethyl)tetrahydro-2H-pyran plays a crucial role in the development of potential treatments for various diseases, including cancer, where the mTOR pathway is often dysregulated.
Additionally, 4-(Aminomethyl)tetrahydro-2H-pyran is used as a reagent in the development of pyrazoloquinolines as PDE10A inhibitors. PDE10A inhibitors are being investigated for their potential in treating schizophrenia, a severe mental disorder that affects millions of people worldwide. The compound's role in the synthesis of these inhibitors highlights its importance in the search for novel treatments for psychiatric conditions.

InChI:InChI=1/C6H13NO/c7-5-6-1-3-8-4-2-6/h6H,1-5,7H2/p+1

Upstream product

• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 125552-89-8 4-(bromomethyl)tetrahydro-2H-pyran 
• 344329-76-6 tetrahydro-pyran-4-carboxylic acid amide 
• 362703-30-8 methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate 

Downstream Products

• 666260-75-9 2-(2,4-dichloroanilino)-N-(tetrahydropyran-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide 
• 874888-77-4 C₁₃H₁₈N₂O₃ 
• 874888-78-5 methyl-(4-nitro-benzyl)-(tetrahydro-pyran-4-ylmethyl)-amine 
• 874888-79-6 4-{[methyl-(tetrahydro-pyran-4-ylmethyl)-amino]-methyl}-phenylamine 
• 874888-80-9 3,4-dichloro-N-(4-{[methyl-(tetrahydro-pyran-4-ylmethyl)-amino]-methyl}-phenyl)-benzamide 
• 666262-72-2 N-(tetrahydro-pyran-4-ylmethyl)-carbamic acid tert-butyl ester 
• 809273-60-7 methyl 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]benzoate 
• 849351-32-2 N-{3-Nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide 
• 849351-10-6 N-methyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide 
• 849351-16-2 N-ethyl-N-{3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}acetamide 
• 389621-78-7 (tetrahydro-2H-pyran-4-yl)methanamine hydrochloride 
• 850069-59-9 7-(benzyloxy)-3-nitro-N-(tetrahydro-2H-pyran-4-ylmethyl)quinolin-4-amine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF VENETOCLAX

The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS

Certain 1H-imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolines, 1H-imidazo[4,5-c][1,5]naphthyridines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]naphthyridines, and 1H-imidazo[4,5-c]pyridines substituted at the 1- and 2-positions, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

METHOD FOR PRODUCING NITRILE COMPOUND, CARBOXYLIC ACID COMPOUND OR CARBOXYLATE COMPOUND

The present invention discloses a process for preparing a nitrile compound, a carboxylic acid compound or a carboxylic acid ester compound represented by the formula (2): wherein R represents a cyano group, a carboxyl group or an ester group, R1 and R2 each represent a group which does not participate in the reaction, which may have a substituent, and R1 and R2 may be combined to each other to form a ring, which comprises subjecting an acetic acid compound represented by the formula (1): wherein R, R1 and R2 have the same meanings as defined above, to decarboxylation in the presence of a metal catalyst.

Thiazolinone 2-substituted quinolines

Thiazolinone substituted quinoline derivatives where the quinoline ring is substituted at the 2 position which derivatives demonstrates CDK1 antiproliferative activity and are useful as anti-cancer agents.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES

Aryl substituted imidazoquinoline compounds, according to formula I, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing w or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral., and neoplastic, are disclosed. formula (I): wherein: R is selected from the group consisting of alkyl, alkoxy, hydroxy, and trifluoromethyl;. N is 0 or 1; R3 is selected from the group consisting of: -Z-Ar,-Z-Ar’-Y-R4, -Z-Ar’-X-Y-R4, Z-Ar’-R5, and-Z-Ar'-X-R5; Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy; heterocyctyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino.

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.